Financials
Financial year 2025
POULPHARM from Izegem, company number BE0888282250, closed financial year 2025 with a result of € 456,285 after tax. For that financial year POULPHARM recorded revenue of € 17 million and equity of € 2.2 million. Compared with financial year 2024, the result moved from € 1.7 million to € 456,285. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.
€ 2.2 million
▲ 27% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 456,285
▼ 74% vs 2024
Profit after tax over the fiscal year.
€ 242,510
▼ 31% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 2.1 million.
People and assets in 2025
106
▲ 25.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 7.7 million
▲ 44% vs 2024
€ 72,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 517,296
▲ 290% vs 2024
Of which on lease € 400,166.
Debts at end 2025
€ 7.8 million
▼ 3% vs 2024
€ 883,519 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 2.3 million
▼ 36% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 81 days on average.
€ 1.4 million
▲ 29% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | € 11,211,427 | € 16,406,901 | € 17,047,385 | ▲ 4% |
| Gross margin | € 6,080,321 | - | - | - | |
| Profit after taxes | € 504,236 | € 827,906 | € 1,727,730 | € 456,285 | ▼ 74% |
| Equity | € 543,360 | € 1,071,266 | € 1,708,996 | € 2,165,282 | ▲ 27% |
| Total debts | € 9,894,387 | € 10,420,821 | € 13,868,212 | € 13,330,851 | ▼ 4% |
| Cash | € 112,440 | € 216,549 | € 352,265 | € 242,510 | ▼ 31% |
| Land & buildings | € 4,475,138 | € 5,941,226 | € 6,490,966 | € 6,159,784 | ▼ 5% |
| Retained profit | € 503,360 | € 1,031,266 | € 1,668,996 | € 2,125,282 | ▲ 27% |
| Dividend | € 500,000 | € 300,000 | € 1,090,000 | € 0 | ▼ 100% |
| Bank debt | € 6,255,913 | € 7,176,859 | € 8,082,505 | € 7,802,140 | ▼ 3% |
| Balance sheet total | € 10,437,747 | € 11,492,088 | € 15,577,208 | € 15,496,132 | ▼ 1% |
| Employees (FTE) | 69.9 | 70.1 | 80.9 | 106 | ▲ 25.1 |
Key figures of POULPHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to POULPHARM?
What happened at POULPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 456,285 (▼ 74% vs 2024). filed late Source: NBB ↗
- New establishment in Izegem. KBO
- New establishment in Aalter. KBO
- New establishment in Zwevegem. KBO
- New establishment in Izegem. KBO
- Start of the company according to the CBE. KBO
- New establishment in Izegem. KBO
In short
From € 504,236 profit in 2022 to € 456,285 profit in 2025.
Paid € 702,761 in corporate taxes since 2022.
Best year ever: 2024, with € 1.7 million profit.
On average € 87,000 of value added per employee in 2022.
A new publication or filing at POULPHARM? We notify you, reason included.
Follow POULPHARMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind POULPHARM is De Sasmeester CommV. De Sasmeester CommV is also behind WAAROOST, IMAQUA, WAAROOST APOTHEEK, RUMEXPERTS and C-Path.
Directors
According to the 2025 annual accounts
Director · represented by Joris Pieter De Gussem
Also active at: WAAROOST, IMAQUA, WAAROOST APOTHEEK, RUMEXPERTS, C-Path, VETPHARM, MYVO
Establishments
Establishment units
Physical locations of this company
Kokelarestraat 83
8870 Izegem
Prins Albertlaan 112
8870 Izegem
Active since 13 March 2007
Pontstraat(H) 93
8551 Zwevegem
Active since 1 November 2012
Wolvenhofstraat 4
8870 Izegem
Active since 1 November 2012
Buntelarestraat 19
9880 Aalter
Active since 20 June 2019
Prins Albertlaan 113
8870 Izegem
Active since 1 December 2023
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 8 companies are registered at this address.
All companies at this address →DE SASMEESTER same network
MANDELSAS
VETPHARM same network
€ 124,072 gross margin · 2025
MYVO same network
€ 2.2 million gross margin · 2025
PHAGOMED
€ -889 gross margin · 2025
+3 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
DIGICERT - Tiggee LLC, US
Website info
Features
Security
Network
Details
- Company number
- 0888.282.250
- VAT number
- BE 0888.282.250
- Registered office
- Kokelarestraat 83, 8870 Izegem
- Names & denominations
- POULPHARM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 27 March 2007
- Peppol
- Active · Active since 20 Nov 2020
- Contact
- poulpharm.be [email protected] 051304100
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Medische laboratoria
Activiteiten van medische beeldvorming en medische laboratoria
Activiteiten van medische laboratoria